U.S. flag

An official website of the United States government

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Parkinson’s disease in adults: diagnosis and management. London: National Institute for Health and Care Excellence (NICE); 2017 Jul. (NICE Guideline, No. 71.)

Cover of Parkinson’s disease in adults: diagnosis and management

Parkinson’s disease in adults: diagnosis and management.

Show details

Appendix JOld guideline references

1.
National Institute for Health and Clinical Excellence. Guideline development methods: information for national collaborating centres and guideline developers. London: National Institute for Health and Clinical Excellence, 2004. Ref ID: 20114
2.
Parkinson’s Disease Society. Parkinson’s disease: the personal view. London: Parkinson’s Disease Society, 1993. Ref ID: 19909
4.
Parkinson’s Disease Society. One in twenty: an information pack for younger people with Parkinson’s. London: Parkinson’s Disease Society, 2002. Ref ID: 19910
14.
Department of Health. The national service framework for long-term (neurological) conditions. London: HMSO, 2005. Ref ID: 19904
25.
Department of Health. The expert patient: a new approach to chronic disease management for the 21st century. London: Department of Health, 2001. Ref ID: 19595
26.
Montgomery EB, Lieberman A, Singh G et al. Patient education and health promotion can be effective in Parkinson’s disease: a randomized controlled trial. PROPATH Advisory Board. American Journal of Medicine. 1994; 97(5):429–435. Ref ID: 737 [PubMed: 7977431]
27.
Mercer BS. A randomized study of the efficacy of the PROPATH program for patients with Parkinson disease. Archives of Neurology. 1996; 53:881–884. Ref ID: 739 [PubMed: 8815853]
28.
Findley L, Eichhorn T, Janca A et al. Factors impacting on quality of life in Parkinson’s disease: results from an international survey. Movement Disorders. 2002; 17(1):60–67. Ref ID: 742 [PubMed: 11835440]
29.
Habermann B. Day-to-day demands of Parkinson’s disease. Western Journal of Nursing Research. 1996; 18(4):397–413. Ref ID: 65 [PubMed: 8797365]
30.
Pentland B, Pitkairn TK, Gray TK. The effects of reduced expression in Parkinson’s disease in impression formation by health professionals. Clinical Rehabilitation. 1987; 1:307–313 Ref ID: 2766
31.
Yarrow, S. Survey of members of the Parkinson’s Disease Society. London: Parkinson’s Disease Society of the United Kingdom and Policy Studies Institute, 1999. Ref ID: 786
32.
Shimbo T, Goto M, Morimoto T et al. Association between patient education and health- related quality of life in patients with Parkinson’s disease. Quality of Life Research. 2004; 13 (1):81–89. Ref ID: 19841 [PubMed: 15058790]
33.
Meadowcroft RS, Scott S, and Woodford C. Communicating with people with Parkinson’s and their carers. London: Parkinson’s Disease Society, 2005. Ref ID: 19903
34.
Bennett DA, Beckett AM, Shannon KM et al. Prevalence of parkinsonian signs and associated mortality in a community population of older people. New England Journal of Medicine. 1996; 334(24):71–76. Ref ID: 2772 [PubMed: 8531961]
35.
Gibb WRG, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson’s disease. Journal of Neurology, Neurosurgery & Psychiatry. 1988; 51(6):745–752 Ref ID: 2773 [PMC free article: PMC1033142] [PubMed: 2841426]
36.
Rajput AH, Rozdilsky B, Rajput A. Accuracy of clinical diagnosis in Parkinsonism - A prospective study. Canadian Journal of Neurological Sciences. 1991; 18(3):275–278. Ref ID: 111 [PubMed: 1913360]
37.
Hughes AJ, Daniel SE, Kilford L et al. Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. Journal of Neurology, Neurosurgery & Psychiatry. 1992; 55(3): 181–184. Ref ID: 99 [PMC free article: PMC1014720] [PubMed: 1564476]
38.
Hughes AJ, Daniel SE, Ben Shlomo Y et al. The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain. 2002; 125(Pt:4):4–70. Ref ID: 96 [PubMed: 11912118]
39.
Schrag A, Ben Shlomo Y, Quinn N. How valid is the clinical diagnosis of Parkinson’s disease in the community? Journal of Neurology, Neurosurgery & Psychiatry. 2002; 73 (5):529–534. Ref ID: 142 [PMC free article: PMC1738115] [PubMed: 12397145]
40.
Meara J, Bhowmick BK, Hobson P. Accuracy of diagnosis in patients with presumed Parkinson’s disease. Age & Ageing. 1999; 28(2):99–102. Ref ID: 108 [PubMed: 10350403]
41.
Jankovic J, Rajput AH, McDermott MP et al. The evolution of diagnosis in early Parkinson disease. Archives of Neurology. 2000; 57(3):369–372. Ref ID: 81 [PubMed: 10714663]
42.
Lees AJ, Katzenschlager R, Head J et al. Ten-year follow-up of three different initial treatments in de-novo PD: a randomized trial. Neurology. 2001; 57(9):1687–1694. Ref ID: 2309 [PubMed: 11706112]
43.
Benamer HT, Oertel WH, Patterson J et al. Prospective study of presynaptic dopaminergic imaging in patients with mild parkinsonism and tremor disorders: part 1. Baseline and 3-month observations. Movement Disorders. 2003; 18(9):977–984. Ref ID: 425 [PubMed: 14502664]
44.
Popperl G, Radau P, Linke R et al. Diagnostic performance of a 3-D automated quantification method of dopamine D2 receptor SPECT studies in the differential diagnosis of parkinsonism. Nuclear Medicine Communications. 2005; 26(1):39–43. Ref ID: 19822 [PubMed: 15604946]
45.
Benamer TS, Patterson J, Grosset DG et al. Accurate differentiation of parkinsonism and essential tremor using visual assessment of [123I]-FP-CIT SPECT imaging: the [123I]-FP CIT study group. Movement Disorders. 2000; 15(3):503–510. Ref ID: 484 [PubMed: 10830416]
46.
Booij J, Speelman JD, Horstink MW et al. The clinical benefit of imaging striatal dopamine transporters with [123I]FP-CIT SPET in differentiating patients with presynaptic parkinsonism from those with other forms of parkinsonism. European Journal of Nuclear Medicine. 2001; 28 (3):266–272. Ref ID: 467 [PubMed: 11315592]
47.
Lokkegaard A, Werdelin LM, Friberg L. Clinical impact of diagnostic SPET investigations with a dopamine re-uptake ligand. European Journal of Nuclear Medicine & Molecular Imaging. 2002; 29(12):1623–1629. Ref ID: 439 [PubMed: 12458397]
48.
Prunier C, Tranquart F, Cottier JP et al. Quantitative analysis of striatal dopamine D2 receptors with 123 I-iodolisuride SPECT in degenerative extrapyramidal diseases. Nuclear Medicine Communications. 2001; 22(11):1207–1214. Ref ID: 459 [PubMed: 11606886]
49.
Parkinson Study Group. A multicenter assessment of dopamine transporter imaging with DOPASCAN/SPECT in parkinsonism. Neurology. 2000; 55(10):1540–1547. Ref ID: 475 [PubMed: 11094111]
50.
Van Laere K, De Ceuninck L, Dom R et al. Dopamine transporter SPECT using fast kinetic ligands: 123I-FP- beta-CIT versus 99mTc-TRODAT-1. European Journal of Nuclear Medicine & Molecular Imaging. 2004; 31(8):1119–1127. Ref ID: 19824 [PubMed: 15064872]
51.
Chou KL, Hurtig HI, Stern MB et al. Diagnostic accuracy of [99mTc]TRODAT-1 SPECT imaging in early Parkinson’s disease. Parkinsonism & Related Disorders. 2004; 10(6):375–379 Ref ID: 19817 [PubMed: 15261880]
52.
Asenbaum S, Pirker W, Angelberger P et al. [123I]beta-CIT and SPECT in essential tremor and Parkinson’s disease. Journal of Neural Transmission. 1998; 105(10-12):1213–1228 Ref ID: 507 [PubMed: 9928890]
53.
Acton PD, Mozley PD, Kung HF. Logistic discriminant parametric mapping: a novel method for the pixel-based differential diagnosis of Parkinson’s disease. European Journal of Nuclear Medicine. 1999; 26(11): 1413–1423. Ref ID: 196 [PubMed: 10552082]
54.
Varrone A, Marek KL, Jennings D et al. [123I]beta-CIT SPECT imaging demonstrates reduced density of striatal dopamine transporters in Parkinson’s disease and multiple system atrophy. Movement Disorders. 2001; 16(6):1023–1032. Ref ID: 453 [PubMed: 11748733]
55.
Huang WS, Lee MS, Lin JC et al. Usefulness of brain 99mTc-TRODAT-1 SPET for the evaluation of Parkinson’s disease. European Journal of Nuclear Medicine & Molecular Imaging. 2004; 31(2):155–161. Ref ID: 19820 [PubMed: 15129696]
56.
Catafau AM, Tolosa E, Laloux P et al. Impact of dopamine transporter SPECT using 123I Ioflupane on diagnosis and management of patients with clinically uncertain parkinsonian syndromes. Movement Disorders. 2004; 19(10):1175–1182. Ref ID: 19823 [PubMed: 15390019]
57.
Weng YH, Yen TC, Chen MC et al. Sensitivity and specificity of 99mTc-TRODAT-1 SPECT imaging in differentiating patients with idiopathic Parkinson’s disease from healthy subjects. Journal of Nuclear Medicine. 2004; 45(3):393–401. Ref ID: 19821 [PubMed: 15001678]
58.
Jennings DL, Seibyl JP, Oakes D et al. [123I]beta-CIT and single-photon emission computed tomographic imaging vs clinical evaluation in Parkinsonian syndrome: unmasking an early diagnosis. Archives of Neurology. 2004; 61(8):1224–1229. Ref ID: 19818 [PubMed: 15313838]
59.
Dodel RC, Hoffken H, Moller JC et al. Dopamine transporter imaging and SPECT in diagnostic work-up of Parkinson’s disease: a decision-analytic approach. Movement Disorders. 2003; 18:(Suppl 7):S52–S62. Ref ID: 19666 [PubMed: 14531047]
60.
Holloway R, Shoulson I, Kieburtz K et al. Pramipexole vs levodopa as initial treatment for Parkinson disease: a randomized controlled trial. Journal of the American Medical Association. 2000; 284(15): 1931–1938. Ref ID: 1477 [PubMed: 11035889]
61.
Whone AL, Watts RL, Stoessl AJ et al. Slower progression of Parkinson’s disease with ropinirole versus levodopa: The REAL-PET study. Annals of Neurology. 2003; 54(1):93–101. Ref ID: 808 [PubMed: 12838524]
62.
Fahn S, Oakes D, Shoulson I et al. Levodopa and the progression of Parkinson’s disease. New England Journal of Medicine. 2004; 351(24):2498–2508. Ref ID: 19725 [PubMed: 15590952]
63.
Burn DJ, Sawle GV, Brooks DJ. Differential diagnosis of Parkinson’s disease, multiple system atrophy, and Steele-Richardson-Olszewski syndrome: discriminant analysis of striatal 18 F-dopa PET data. Journal of Neurology, Neurosurgery & Psychiatry. 1994; 57(3):278–284. Ref ID: 329 [PMC free article: PMC1072814] [PubMed: 8158173]
64.
Schocke MFH, Seppi K, Esterhammer R et al. Diffusion-weighted MRI differentiates the Parkinson variant of multiple system atrophy from PD. Neurology. 2002; 58(4):575–580. Ref ID: 130 [PubMed: 11865135]
65.
Cercy SP, Bylsma FW. Lewy bodies and progressive dementia: A critical review and meta-analysis. Journal of the International Neuropsychological Society. 1997; 3(2):179–194. Ref ID: 29 [PubMed: 9126859]
66.
Bhattacharya K, Saadia D, Eisenkraft B et al. Brain magnetic resonance imaging in multiple-system atrophy and Parkinson disease: A diagnostic algorithm. Archives of Neurology. 2002; 59(5):835–842. Ref ID: 13 [PubMed: 12020268]
67.
Juh R, Kim J, Moon D et al. Different metabolic patterns analysis of Parkinsonism on the 18 F-FDG PET. European Journal of Radiology. 2004; 51(3):223–233. Ref ID: 19839 [PubMed: 15294329]
68.
Schreckenberger M, Hagele S, Siessmeier T et al. The dopamine D2 receptor ligand 18F- desmethoxy-fallypride: An appropriate fluorinated PET tracer for the differential diagnosis of parkinsonism. European Journal of Nuclear Medicine & Molecular Imaging. 2004; 31 (8):1128–1135. Ref ID: 19838 [PubMed: 15042325]
69.
Eidelberg D, Moeller JR, Ishikawa T et al. Early differential diagnosis of Parkinson’s disease with 18F-fluorodeoxyglucose and positron emission tomography. Neurology. 1995; 45 (11):1995–2004. Ref ID: 291 [PubMed: 7501148]
70.
Sawle GV, Playford ED, Burn DJ et al. Separating Parkinson’s disease from normality. Discriminant function analysis of fluorodopa F 18 positron emission tomography data. Archives of Neurology. 1994; 51(3):237–243. Ref ID: 213 [PubMed: 8129633]
71.
Righini A, Antonini A, Ferrarini M et al. Thin section MR study of the basal ganglia in the differential diagnosis between striatonigral degeneration and Parkinson disease. Journal of Computer Assisted Tomography. 2002; 26(2):266–271. Ref ID: 129 [PubMed: 11884785]
72.
Seppi K, Schocke MFH, Esterhammer R et al. Diffusion-weighted imaging discriminates progressive supranuclear palsy from PD, but not from the parkinson variant of multiple system atrophy. Neurology. 2003; 60(6):922–927. Ref ID: 133 [PubMed: 12654954]
73.
Yekhlef F, Ballan G, Macia F et al. Routine MRI for the differential diagnosis of Parkinson’s disease, MSA, PSP, and CBD. Journal of Neural Transmission. 2003; 110 (2):151–169. Ref ID: 135 [PubMed: 12589575]
74.
Price S, Paviour D, Scahill R et al. Voxel-based morphometry detects patterns of atrophy that help differentiate progressive supranuclear palsy and Parkinson’s disease. Neuroimage. 2004; 23(2):663–669. Ref ID: 19826 [PubMed: 15488416]
75.
Righini A, Antonini A, De Notaris R et al. MR imaging of the superior profile of the midbrain: Differential diagnosis between progressive supranuclear palsy and Parkinson disease. American Journal of Neuroradiology. 2004; 25(6):927–932. Ref ID: 19827 [PMC free article: PMC7975674] [PubMed: 15205125]
76.
Paviour DC, Price SL, Stevens JM et al. Quantitative MRI measurement of superior cerebellar peduncle in progressive supranuclear palsy. Neurology. 2005; 64(4):675–679. Ref ID: 19831 [PubMed: 15728291]
77.
Cordato NJ, Pantelis C, Halliday GM et al. Frontal atrophy correlates with behavioural changes in progressive supranuclear palsy. Brain. 2002; 125(4):789–800. Ref ID: 123 [PubMed: 11912112]
78.
Clarke CE, Lowry M. Systematic review of proton magnetic resonance spectroscopy of the striatum in parkinsonian syndromes. European Journal of Neurology. 2001; 8(6):573–577 Ref ID: 17 [PubMed: 11784341]
79.
Clarke CE, Davies P. Systematic review of acute levodopa and apomorphine challenge tests in the diagnosis of idiopathic Parkinson’s disease. Journal of Neurology, Neurosurgery & Psychiatry. 2000; 69(5):590–594. Ref ID: 21 [PMC free article: PMC1763425] [PubMed: 11032609]
80.
Rossi P, Colosimo C, Moro E et al. Acute challenge with apomorphine and levodopa in Parkinsonism. European Neurology. 2000; 43(2):95–101. Ref ID: 719 [PubMed: 10686467]
82.
Hughes AJ, Lees AJ, Stern GM. Apomorphine test to predict dopaminergic responsiveness in parkinsonian syndromes. Lancet. 1990; 336(8706):32–34. Ref ID: 84 [PubMed: 1973218]
83.
D’Costa DF, Abbott RJ, Pye IF et al. The apomorphine test in parkinsonian syndromes. Journal of Neurology, Neurosurgery & Psychiatry. 1991; 54(10):870–872. Ref ID: 79 [PMC free article: PMC1014569] [PubMed: 1744640]
84.
Zappia M, Montesanti R, Colao R et al. Short-term levodopa test assessed by movement time accurately predicts dopaminergic responsiveness in Parkinson’s disease. Movement Disorders. 1997; 12(1):103–106. Ref ID: 731 [PubMed: 8990062]
85.
Double KL, Rowe DB, Hayes M et al. Identifying the pattern of olfactory deficits in Parkinson disease using the brief smell identification test. Archives of Neurology. 2003; 60 (4):545–549. Ref ID: 699 [PubMed: 12707068]
86.
Muller A, Mungersdorf M, Reichmann H et al. Olfactory function in Parkinsonian syndromes. Journal of Clinical Neuroscience. 2002; 9(5):521–524. Ref ID: 700 [PubMed: 12383407]
87.
Wenning GK, Shephard B, Hawkes C et al. Olfactory function in atypical parkinsonian syndromes. Acta Neurologica Scandinavica. 1995; 91(4):247–250. Ref ID: 707 [PubMed: 7625148]
88.
Antonini A, Benti R, De Notaris R et al. 123I-ioflupane/SPECT binding to striatal dopamine transporter (DAT) uptake in patients with Parkinson’s disease, multiple system atrophy, and progressive supranuclear palsy. Neurological Sciences. 2003; 24(3):149–150. Ref ID: 789 [PubMed: 14598060]
89.
Hawkes CH, Shephard BC, Daniel SE. Olfactory dysfunction in Parkinson’s disease. Journal of Neurology, Neurosurgery & Psychiatry. 1997; 62(5):436–446. Ref ID: 703 [PMC free article: PMC486843] [PubMed: 9153598]
90.
Doty RL, Bromley SM, Stern MB. Olfactory testing as an aid in the diagnosis of Parkinson’s disease: development of optimal discrimination criteria. Neurodegeneration. 1995; 4(1):93–97. Ref ID: 708 [PubMed: 7600189]
92.
Mesholam RI, Moberg PJ, Mahr RN et al. Olfaction in neurodegenerative disease: a meta-analysis of olfactory functioning in Alzheimer’s and Parkinson’s diseases. Archives of Neurology. 1998; 55(1):84–90. Ref ID: 702 [PubMed: 9443714]
93.
Mitchell A, Lewis S, Foltynie T et al. Biomarkers and Parkinson’s disease. Brain. 2004; 127:1693–1705. Ref ID: 19536 [PubMed: 15215212]
94.
Clarke CE. A ‘cure’ for Parkinson’s disease: can neuroprotection be proven with current trial designs? Movement Disorders. 2004; 19:491–499. Ref ID: 19538 [PubMed: 15133811]
95.
Clarke CE. Parkinson’s disease in practice. London: Royal Society of Medicine Press, 2001 Ref ID: 2
96.
Schapira A. Disease modification in Parkinson’s disease. Lancet Neurology. 2004; 3:362–368. Ref ID: 19537 [PubMed: 15157851]
97.
Clarke CE, Guttman M. Dopamine agonist monotherapy in Parkinson’s disease. Lancet. 2002; 360(9347):1767–1769. Ref ID: 16 [PubMed: 12480442]
98.
Clarke CE. Neuroprotection and pharmacotherapy for motor symptoms in Parkinson’s disease. Lancet Neurology. 2004; 3:466–475. Ref ID: 19540 [PubMed: 15261607]
99.
Parkinson Study Group. A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. Archives of Neurology. 2004; 61(4):561–566. Ref ID: 2764 [PubMed: 15096406]
100.
Ravina BM, Fagan SC, Hart RG. Neuroprotective agents for clinical trials in Parkinson’s disease. Neurology. 2003; 60:1234–1240. Ref ID: 19541 [PubMed: 12707423]
101.
Shults CW. Effect of selegiline (deprenyl) on the progression of disability in early Parkinson’s disease. Parkinson Study Group. Acta Neurologica Scandinavica Supplementum. 1993; 146:36–42. Ref ID: 805 [PubMed: 8333252]
102.
Kieburtz K, McDermott M, Como P et al. The effect of deprenyl and tocopherol on cognitive performance in early untreated Parkinson’s disease. Neurology. 1994; 44(9):1756–1759 Ref ID: 281 [PubMed: 7936311]
103.
Koller W, Olanow CW, Rodnitzky R et al. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson’s disease. New England Journal of Medicine. 1993; 328(3):176–183. Ref ID: 148 [PubMed: 8417384]
104.
Shoulson I. Deprenyl and tocopherol antioxidative therapy of parkinsonism (DATATOP). Acta Neurologica Scandinavica Supplementum. 1989; 80(126):171–175. Ref ID: 363 [PubMed: 2515723]
105.
Parker W, Boyson S, Parks J. Abnormalities of the electron transport chain in idiopathic Parkinson’s disease. Annals of Neurology. 1989; 26:719–723. Ref ID: 19543 [PubMed: 2557792]
106.
Schapira A, Mann V, Cooper J. Anatomic and disease specificity of NADH CoQ1 reductase (complex 1) deficiency in Parkinson’s disease. Journal of Neurochemistry. 1990; 55:2142–2145. Ref ID: 19544 [PubMed: 2121905]
107.
Shults C, Haas R, Passov D et al. Coenzyme Q10 levels correlate with the activities of the complex I and II/III mitochrondria from parkinsonian and non-parkinsonian subjects. Annals of Neurology. 1997; 42:261–264. Ref ID: 19545 [PubMed: 9266740]
108.
Beal MF, Matthews R, Tieleman A et al. Coenzyme Q10 attenuates the MPTP induced loss of striatal dopamine and dopaminergic axons in aged mice. Brain Research. 1998; 783:109–114. Ref ID: 19546 [PubMed: 9479058]
109.
Muller T, Buttner T, Gholipour AF et al. Coenzyme Q10 supplementation provides mild symptomatic benefit in patients with Parkinson’s disease. Neuroscience Letters. 2003; 341 (3):201–204. Ref ID: 799 [PubMed: 12697283]
110.
Shults CW, Oakes D, Kieburtz K et al. Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. Archives of Neurology. 2002; 59 (10):1541–1550. Ref ID: 801 [PubMed: 12374491]
111.
Lida M, Miyazaki I, Tanaka K et al. Dopamine D2 receptor-mediated antioxidant and neuroprotective effects of ropinirole, a dopamine agonist. Brain Research. 1999; 838:51–59. Ref ID: 19547 [PubMed: 10446316]
112.
Schapira A, Olanow CW. Rationale for the use of dopamine agonists as neuroprotective agents in Parkinson’s disease. Annals of Neurology. 2003; 53:S149–S157. Ref ID: 19549 [PubMed: 12666106]
113.
Marek K. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. Journal of the American Medical Association. 2002; 287(13):1653–1661. Ref ID: 809 [PubMed: 11926889]
114.
Rakshi JS, Pavese N, Uema T et al. A comparison of the progression of early Parkinson’s disease in patients started on ropinirole or L-dopa: an 18F-dopa PET study. Journal of Neural Transmission. 2002; 109(12):1433–1443. Ref ID: 2535 [PubMed: 12486484]
115.
Przuntek H, Welzel D, Blumner E et al. Bromocriptine lessens the incidence of mortality in L-dopa-treated parkinsonian patients: prado-study discontinued. European Journal of Clinical Pharmacology. 1992; 43(4):357–363. Ref ID: 2518 [PubMed: 1451713]
116.
Hely MA, Morris JG, Traficante R et al. The sydney multicentre study of Parkinson’s disease: progression and mortality at 10 years. Journal of Neurology, Neurosurgery & Psychiatry. 1999; 67(3):300–307. Ref ID: 2184 [PMC free article: PMC1736543] [PubMed: 10449550]
117.
Montastruc JL, Desboeuf K, Lapeyre-Mestre M et al. Long-term mortality results of the randomized controlled study comparing bromocriptine to which levodopa was later added with levodopa alone in previously untreated patients with Parkinson’s disease. Movement Disorders. 2001; 16(3):511–514. Ref ID: 2414 [PubMed: 11391747]
118.
Rinne UK, Bracco F, Chouza C et al. Early treatment of Parkinson’s disease with Cabergoline delays the onset of motor complications. Results of a double-blind levodopa controlled trial. Drugs. 1998; 55:(Suppl 1):23–3TxCM 20. Ref ID: 19605 [PubMed: 9483167]
119.
Hundemer HP, Lledo A, Van Laar T et al. The safety of pergolide monotherapy in early stage Parkinson’s disease. One year interim analysis of a 3 year double blind randomised study of pergolide versus levodopa (abstract). Movement Disorders. 2000; 15 (Supplement 3):115. Ref ID: 19598
120.
Ives NJ, Stowe RL, Marro J et al. Monoamine oxidase type B inhibitors in early Parkinsons’s disease: meta analysis of 17 randomised trials involving 3525 patients. British Medical Journal. 2004; 329(7466): 593–596. Ref ID: 2739 [PMC free article: PMC516655] [PubMed: 15310558]
121.
Macleod AD, Counsell CE, Ives N et al. Monoamine oxidase B inhibitors for early Parkinson’s disease. The Cochrane Database of Systematic Reviews. 2005;(3):CD004898. Ref ID: 20026 [PMC free article: PMC8859569] [PubMed: 16034956]
360.
Parkinson’s Disease Society. Competencies: an integrated career and competency framework for nurses working in PD management. London: Parkinson’s Disease Society, 2005 Ref ID: 19937
361.
Bell L. Changing roles: the impact of Parkinson’s disease nurse specialists. London: Parkinson’s Disease Society, 2004. Ref ID: 787
362.
Jarman B, Hurwitz B, Cook A. Effects of community based nurses specialising in Parkinson’s disease on health outcome and costs: randomised controlled trial. British Medical Journal. 2002; 324(7345): 1072–1075. Ref ID: 223 [PMC free article: PMC104336] [PubMed: 11991913]
363.
Jahanshahi M, Brown RG, Whitehouse C et al. Contact with a nurse practitioner: A short-term evaluation study in Parkinson’s disease and dystonia. Behavioural Neurology. 1994; 7(3–4):189–196. Ref ID: 200 [PubMed: 24487336]
364.
Reynolds H, Wilson-Barnett J, Richardson G. Evaluation of the role of the Parkinson’s disease nurse specialist. International Journal of Nursing Studies. 2000; 37(4):337–349. Ref ID: 744 [PubMed: 10760541]
365.
Hobson P, Roberts S, Meara J. The economic value of a Parkinson’s disease nurse specialist service. Health and Ageing. (3); ii–iii. 2003. Ref ID: 19668
Copyright © NICE 2017.
Bookshelf ID: NBK535862
Contents

Views

Other titles in this collection

Related NICE guidance and evidence

Related information

  • PMC
    PubMed Central citations
  • PubMed
    Links to PubMed

Recent Activity

ClearTurn OffTurn On

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...